B Cell Lymphoma – BiotechReality – Information Intelligence System for Biopharma

NORTH CHICAGO, Ill. - Relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) patients may benefit from safe and efficient outpatient monitoring of epcoritamab, according to revised results from the Phase 2 EPCORE® NHL-6 clinical trial announced by AbbVie today. According to the results, which were presented at the 13th Society of Hematologic Oncology (SOHO) Annual Meeting, this new T-cell-engaging bispecific antibody may provide patients with a more practical treatment choice, hence expanding access to care, especially in community settings. The study demonstrated that epcoritamab can be administered on an outpatient basis. An overwhelming 92% of the 88 patients who got the treatment's first complete dose were under outpatient monitoring. The frequency of adverse effects, including immune cell-associated neurotoxicity syndrome (ICANS) and cytokine release syndrome (CRS), was in line with other research. 40.2% of patients experienced CRS, which was mostly low-grade and resolved in a median of two days without requiring treatment to be stopped. In a similar vein, 7.6% of patients experienced ICANS, which was primarily low-grade and went away in a median of three days without requiring medication withdrawal. Read More: AbbVie Reports Breakthrough Results for RINVOQ® (Upadacitinib) in Alopecia Areata Treatment Additionally, the trial showed encouraging efficacy. The complete response (CR) rate was 47.6% and the overall response rate (ORR) was 64.3% in patients who had only received one previous line of therapy. The ORR and CR rates for patients who had received two or more lines of therapy before were 60.0% and 38.0%, respectively. The most prevalent kind of non-Hodgkin's lymphoma is DLBCL, and in many cases, the cancer either recurs or develops resistance to therapy. The purpose of the 92-patient EPCORE® NHL-6 trial was to evaluate the safety of epcoritamab administered as an outpatient procedure. Read More: AbbVie Enters Into the Obesity Drug Market With a License Agreement Genmab and AbbVie collaborated to create the IgG1-bispecific antibody epcoritamab. It is applied subcutaneously and functions by activating T-cells and cells that express CD20, which results in the destruction of the malignant cells by T-cells. For the treatment of adult patients with relapsed or refractory DLBCL, not otherwise specified, including DLBCL resulting from indolent lymphoma, and high-grade B-cell lymphoma following two or more lines of systemic therapy, the U.S. Food and Drug Administration (FDA) has approved EPKINLY® (epcoritamab-bysp). The FDA's Accelerated designation program awarded this designation based on response durability and response rate. A confirmatory trial may be required to verify and describe the clinical benefit before this indication can continue to be approved. Information: AbbVie Last Modified:

Tag: B Cell Lymphoma

AbbVie Announces Promising Results for Outpatient Use of Epcoritamab in Lymphoma Treatment

Allogene Therapeutics Pivots to Standard Lymphodepletion in ALPHA3 Trial Following Patient Death

Areas Covered

Discover More

GSK Secures Japan Orphan Drug Designation for Risvutatug Rezetecan in Small-Cell Lung Cancer

Pfizer’s Talzenna + Xtandi Delivers Proven rPFS Breakthrough in HRR-Mutated mCSPC

Eli Lilly Declares Powerful 2% A1C Reduction and 17% Weight Loss in Landmark Phase 3 Trial Results of Retatrutide

ICOTYDE FDA Approval: J&J’s First-Line Oral Peptide Breakthrough for Plaque Psoriasis Treatment

Atirmociclib Phase 2 Breakthrough: Pfizer Declares Powerful Results for Metastatic Breast Cancer Treatment

EBGLYSS (lebrikizumab-lbkz) Delivers Remarkable Phase 3 Results for Pediatric Atopic Dermatitis Treatment